Cytochrome P450 and xenobiotic receptor humanized mice

被引:108
作者
Gonzalez, FJ [1 ]
Yu, AM
机构
[1] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
关键词
CYP; nuclear receptor; transgenic mouse model; drug metabolism; pharmacokinetics; pharmacogenetics; cancer; toxicity; ligands; gene activation;
D O I
10.1146/annurev.pharmtox.45.120403.100007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most xenobiotics that enter the body are subjected to metabolism that functions primarily to facilitate their elimination. Metabolism of certain xenobiotics can also result in the production of electrophilic derivatives that can cause cell toxicity and transformation. Many xenobiotics can also activate receptors that in turn induce the expression of genes encoding xenobiotic-metabolizing enzymes and xenobiotic transporters. However, there are marked species differences in the way mammals respond to xenobiotics, which are due in large part to molecular differences in receptors and xenobiotic-metabolizing enzymes. This presents a problem in extrapolating data obtained with rodent model systems to humans. There are also polymorphisms in xenobiotic-metabolizing enzymes that can impact drug therapy and cancer susceptibility. In an effort to generate more reliable in vivo systems to study and predict human response to xenobiotics, humanized mice are under development.
引用
收藏
页码:41 / 64
页数:30
相关论文
共 142 条
[101]  
Obach RS, 2001, DRUG METAB DISPOS, V29, P347
[102]   Peroxisome proliferator activated receptor-α expression in human liver [J].
Palmer, CNA ;
Hsu, MH ;
Griffin, KJ ;
Raucy, JL ;
Johnson, EF .
MOLECULAR PHARMACOLOGY, 1998, 53 (01) :14-22
[103]   Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation [J].
Pascussi, JM ;
Gerbal-Chaloin, S ;
Fabre, JM ;
Maurel, P ;
Vilarem, MJ .
MOLECULAR PHARMACOLOGY, 2000, 58 (06) :1441-1450
[104]   GENETIC-POLYMORPHISM OF CYTOCHROME-P4502E1 IN A SWEDISH POPULATION - RELATIONSHIP TO INCIDENCE OF LUNG-CANCER [J].
PERSSON, I ;
JOHANSSON, I ;
BERGLING, H ;
DAHL, ML ;
SEIDEGARD, J ;
RYLANDER, R ;
RANNUG, A ;
HOGBERG, J ;
SUNDBERG, MI .
FEBS LETTERS, 1993, 319 (03) :207-211
[105]   Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643 [J].
Peters, JM ;
Cattley, RC ;
Gonzalez, FJ .
CARCINOGENESIS, 1997, 18 (11) :2029-2033
[106]  
QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504
[107]   CARCINOGENESIS BY HEPATIC PEROXISOME PROLIFERATORS - EVALUATION OF THE RISK OF HYPOLIPIDEMIC DRUGS AND INDUSTRIAL PLASTICIZERS TO HUMANS [J].
REDDY, JK ;
LALWAI, ND .
CRC CRITICAL REVIEWS IN TOXICOLOGY, 1983, 12 (01) :1-58
[108]   OXIDATIVE DNA DAMAGE CAUSED BY PERSISTENT PEROXISOME PROLIFERATION - ITS ROLE IN HEPATOCARCINOGENESIS [J].
REDDY, JK ;
RAO, MS .
MUTATION RESEARCH, 1989, 214 (01) :63-68
[109]   Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics [J].
Rettie, AE ;
Jones, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :477-494
[110]   Transgenic mouse models of human CYP3A4 gene regulation [J].
Robertson, GR ;
Field, J ;
Goodwin, B ;
Bierach, S ;
Tran, M ;
Lehnert, A ;
Liddle, C .
MOLECULAR PHARMACOLOGY, 2003, 64 (01) :42-50